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INTRODUCTION: Metastatic melanoma is the 
most lethal skin cancer. The prognosis for patients 
with distant metastasis is particularly poor and the 
5-year survival rate is a dismal 20% [1]. To improve
these disappointing statistical figures, it is essential
to better understand the tumour’s behaviour,
progression and response and/or resistance to
treatment options. Recent advances in tissue
engineering enable the development of more
physiologically relevant models that can
recapitulate important features of the tumour tissue,
i.e., the so-called tumour microenvironment (TME).
More specifically, biomaterial based scaffolds can
simulate important topological tissue features that
affect the disease’s progression and response to
treatment, such as porosity, structure, extracellular
matrix presence, cell-cell and cell-matrix 
interactions, environmental gradients and 
vascularization [2-4]. To date, the most effective 
treatment for melanoma is early diagnosis followed 
by surgical resection. Towards rapid diagnosis, 
minimally invasive microneedles are solid or 
hollow microstructures that enable rapid and pain-
free biomarker detection in situ [5].  The aim of this 
work was to develop and further validate the S100, 
a marker that is upregulated in melanoma, on a 
microporous polymer based 3D melanoma model. 
S100 expression in the model was confirmed using 
an immunodiagnostic microneedle device. 
METHODS: The overall procedure followed is 
depicted in Figure 1. 3D polymer (PU) based 
microporous scaffolds were developed and the 
metastatic melanoma cell line A-375 was injected 
and cultivated in those scaffolds for 5 weeks. 
Quantitative assessment of cell viability took place 
with the MTS metabolic assay and evaluation of cell 
distribution within the PU matrix was conducted 
with Scanning Electron Microscopy (SEM). Viable 
(live) cells were visualised in situ with confocal 
laser scanning microscopy (CLSM) of several 
sections of each scaffold. Furthermore, the detection 
of the S100 melanoma specific marker was carried 
out with microneedles via immunoassay analysis on 
their surface.  
Fig 1. Developed platform for S100 detection in the 
3D melanoma model. 
RESULTS: The 3D microporous scaffolds were 
able to support the long term cultivation of the A-
375 cells, with the majority of them being viable 
until the culture endpoint. Dense melanoma cell 
masses adhered to the scaffold pores and were 
distributed throughout the 3D matrix. Additionally 
S100 detection was achieved via immunodiagnostic 
microneedle administration on the surface of the 3D 
scaffolds.   
DISCUSSION & CONCLUSIONS: Our findings 
indicate that this 3D polymer based microporous 
system is a promising tool for ex vivo modelling of 
metastatic melanoma. Furthermore, to our 
knowledge, this is the first time that a 3D in vitro 
melanoma model is used for validation of biomarker 
detection with microneedles. Our findings suggest 
that this 3D microporous melanoma scaffold can be 
used as a low cost tool for validation/screening of 
novel cancer detection methods and/or kits, 
replacing and/or reducing animal testing for the 
validation of such kits. 
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